Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches Early clinical case from CELESTIAL-301 trial, the first-in-human KIR-CAR clinical trial in patients with relapsed/refractory B cell non-Hodgkin lymphoma...